ritodrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
sympathomimetics 2390 26652-09-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • DU21220
  • yutopar
  • ritodrine
  • lavopa
  • ritodrine hydrochloride
  • ritodrine HCl
An adrenergic beta-2 agonist used to control PREMATURE LABOR.
  • Molecular weight: 287.36
  • Formula: C17H21NO3
  • CLOGP: 1.65
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -3.21
  • ROTB: 6
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.97 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 31 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.64 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.60 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 65 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 38
kinase-selectivity-class ACVR2A,ACVR2B,ACVRL1,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAPK12,PRKCD,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ULK1,ULK2 25
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Jan. 22, 1991 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Maternal exposure during pregnancy 216.48 176.74 80 467 359983 90267917
Exposure during pregnancy 207.86 176.74 70 477 238340 90389560
Premature delivery 188.46 176.74 44 503 38718 90589182

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 232.95 165.30 62 324 167362 110421551
Maternal exposure during pregnancy 229.47 165.30 67 319 254816 110334097
Premature delivery 199.23 165.30 40 346 30592 110558321

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G02CA01 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Sympathomimetics, labour repressants
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D012102 Reproductive Control Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D015149 Tocolytic Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D058666 Adrenergic beta-2 Receptor Agonists

Related Drugs by ATC class:

G02CA Sympathomimetics, labour repressants 2 drugs
bupheninefenoterol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Premature labor indication 6383007
Chorioamnionitis contraindication 11612004
Gestational diabetes mellitus contraindication 11687002 DOID:11714
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Antepartum hemorrhage contraindication 34842007
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Mild pre-eclampsia contraindication 41114007
Conduction disorder of the heart contraindication 44808001
Severe pre-eclampsia contraindication 46764007
Pulmonary hypertension contraindication 70995007 DOID:6432
Eclampsia in pregnancy contraindication 198992004
Fetal death contraindication 276507005
Hypertensive urgency contraindication 443482000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.35 acidic
pKa2 11.01 acidic
pKa3 8.82 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST EC50 7.62 WOMBAT-PK CHEMBL
Beta-3 adrenergic receptor GPCR EC50 6.72 WOMBAT-PK

External reference:

IDSource
4019928 VUID
N0000148013 NUI
D01263 KEGG_DRUG
4018621 VANDF
4019928 VANDF
C0035661 UMLSCUI
CHEBI:8872 CHEBI
CHEMBL83063 ChEMBL_ID
CHEMBL1367605 ChEMBL_ID
DB00867 DRUGBANK_ID
D012312 MESH_DESCRIPTOR_UI
33572 PUBCHEM_CID
7294 IUPHAR_LIGAND_ID
2608 INN_ID
23239-51-2 SECONDARY_CAS_RN
I0Q6O6740J UNII
105470 RXNORM
1276 MMSL
1407 MMSL
5430 MMSL
d00603 MMSL
001813 NDDF
004732 NDDF
372893009 SNOMEDCT_US
86257005 SNOMEDCT_US
89785009 SNOMEDCT_US
I0Q6O6740J INXIGHT DRUGS

Pharmaceutical products:

None